Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.
Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug-Drug Interaction Potential of Mavorixafor
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- X4 Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06914869
- Locations
- 🇺🇸
Parexel International LLC, Baltimore, Maryland, United States
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- University of Toronto
- Target Recruit Count
- 26
- Registration Number
- NCT06823596
- Locations
- 🇨🇦
Maple Leaf Medical Clinic, Toronto, Ontario, Canada
🇨🇦Unity Health Toronto -St. Michael's Hospital, Toronto, Ontario, Canada
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT06797674
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc ( Site 0001), Daytona Beach, Florida, United States
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06698016
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0001), Overland Park, Kansas, United States
A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 172
- Registration Number
- NCT05995249
- Locations
- 🇺🇸
Celerion - Tempe, AZ Site, Tempe, Arizona, United States
An Open-label DDI Study of Omaveloxolone in Healthy Subjects
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT05909644
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05560360
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT05330273
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Reverse Triple Negative Immune Resistant Breast Cancer
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05076682
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT05067439
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.